Revance Therapeutics Inc (NASDAQ:RVNC) currently has a daily average trading volume of 3.76M but it saw 1485380 shares traded in last market. With a market cap of 452.13M USD, the company’s current market price of $4.31 came rising about 1.65 while comparing to the previous closing price of $4.24. In past 52 weeks, the stock remained buoying in the range of price level as high as $9.74 and as low as $2.30. In the recent trading on the day, stock has struck highest price mark of $4.17 while lowest mark touched by it was $4.365.
Taking a look at 20-day trading activity of Revance Therapeutics Inc (RVNC) gives us an average price of $5.18, while its current price level is -55.77% below from 52-week high level whereas it is 87.39% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $5.46 while that of 200 days or SMA-200 reads an average of $4.64. A closer look into the stock’s movement over the week reveals that its volatility is standing at 15.42% during that period while stretching the period over a month that decreases to 6.51%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 38.37 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Mizuho which downgraded the stock as “Neutral” in its note to investors issued on January 29, 2024, recommending a price target of between $16 and $9 for it. Goldman downgraded its recommendation for the stock as a “Neutral” from “Buy” on January 09, 2024 while assigning a price target range of $30-$8. Exane BNP Paribas issued its recommendations for the stock as it upgraded the price target for the stock is $20.
Over the week, RVNC’s stock price is moving -25.43% down while it is -18.37% when we observe its performance for the past one month. Year-to-date it is -50.97% down and over the past year, the stock is showing a downside performance of -36.24%.
The latest quarterly earnings report issued by the company reported quarterly earnings per share (EPS) of -0.61 beat the consensus estimate of -0.92 for the same. The company is expected to be releasing its next quarterly report on 2025-Feb-26, for which analysts forecasted an EPS of -0.4 while estimate for next year EPS is -1.51. In next quarter, company is expected to be making quarterly sales of $69.3M as analysts are expecting the sales for current fiscal year at $266.24M and seeing the company making $344.02M in sales next year. Moreover, analysts are in estimates of $83.35M for current-quarter revenue.
Currently, Revance Therapeutics Inc’s total number of outstanding shares is 104.90M. Company’s return on investment (ROI) stands at -62.94% and return on equity (ROE) at -2096.78%. Stock’s beta reads 0.86. Stock has a price to sale or P/S ratio amounts to 1.83. Its return on asset (ROA) is -36.38% on average.
